Structural basis for selective inhibition of Cyclooxygenase-1 (COX-1) by diarylisoxazoles mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6).
Cingolani, G., Panella, A., Perrone, M.G., Vitale, P., Di Mauro, G., Fortuna, C.G., Armen, R.S., Ferorelli, S., Smith, W.L., Scilimati, A.(2017) Eur J Med Chem 138: 661-668
- PubMed: 28710965 
- DOI: https://doi.org/10.1016/j.ejmech.2017.06.045
- Primary Citation of Related Structures:  
5U6X, 5WBE - PubMed Abstract: 
The diarylisoxazole molecular scaffold is found in several NSAIDs, especially those with high selectivity for COX-1. Here, we have determined the structural basis for COX-1 binding to two diarylisoxazoles: mofezolac, which is polar and ionizable, and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6) that has very low polarity. X-ray analysis of the crystal structures of COX-1 bound to mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole allowed the identification of specific binding determinants within the enzyme active site, relevant to generate structure/activity relationships for diarylisoxazole NSAIDs.
Organizational Affiliation: 
Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA; Institute of Biomembranes and Bioenergetics, National Research Council, Via Amendola 165/A, 70125 Bari, Italy.